emjreviews.com
Cure8 news brief
Acne Rates Higher Than Expected in IBD Treatment
Medications
Upadacitinib
JAK inhibitor
Clinical study
Adult patients
Teens
Clinicians
Inflammatory bowel disease
Why This Matters
This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.
Who Should Pay Attention
IBD patients considering or taking upadacitinib (including teens and young adults), their caregivers, and clinicians who prescribe or manage JAK inhibitors.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
A single-center survey of 100 IBD patients treated with upadacitinib found new or worsening acne in about half of respondents, with many requiring dermatology care or prescription treatments. Acne led to dose reduction, therapy changes, or discontinuation in a minority (about 17%) of patients, though most felt the drug’s benefits outweighed the skin effects.
The report emphasizes that acne after starting upadacitinib can be more than mild cosmetic bother — a notable share described moderate or severe disease and some needed ongoing dermatologic management. Younger patients had higher rates. The authors suggest counseling patients before starting upadacitinib and arranging early dermatology input if acne appears.
How this was reported: The article summarizes a cross-sectional survey from a prospective IBD biobank at a tertiary center and cites a Crohn’s & Colitis 360 publication. It does not provide randomized trial data; findings reflect real-world patient reports from one center.
Practical points: If you or a patient are starting upadacitinib, expect discussion about possible acne, consider early skin-care strategies, and know dermatology referral may be needed. Treatment changes for acne occurred but were uncommon.
Keep In Mind
The findings come from a single-center survey (100 patients) and reflect patient-reported outcomes rather than randomized trial data. This does not mean people should stop treatment; rather, anticipate and manage acne proactively. The original Crohn’s & Colitis 360 paper is the primary source for study details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationemjreviews.com
Indexed viaBing News
Source typeResearch news
PublishedMay 14, 2026, 10:03 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
No new safety risks for upadacitinib in IBD at 3 years; uptick in herpes zoster in Crohn’s
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.